Allergan PLC (AGN)

238.13
1.80 0.75
NYSE : Health Care
Prev Close 236.35
Open 238.00
Day Low/High 237.15 / 238.63
52 Wk Low/High 184.50 / 261.27
Volume 252.39K
Avg Volume 3.00M
Exchange NYSE
Shares Outstanding 335.58M
Market Cap 79.85B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.20%)

Latest News

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Weekly Roundup

Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

Allergan Partners With TARGET PharmaSolutions To Advance NASH Research

Allergan Partners With TARGET PharmaSolutions To Advance NASH Research

-- Five-Year Study to Enroll 15,000 Adults and Children with NAFLD or NASH --

Updates on Some Names in Our Portfolio

Taking a look at Facebook, Arconic, Magellan and others.

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Some recent high-flying biotechs may be preparing for their next surge.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

Allergan Launches Frames Of Mind, Encouraging People Living With Migraine To Share Common Experiences Through Art

Allergan Launches Frames Of Mind, Encouraging People Living With Migraine To Share Common Experiences Through Art

Campaign educates on the debilitating impact of migraine on patients' everyday lives

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Allergan Receives 2017 ENERGY STAR® Partner Of The Year - Sustained Excellence Award From U.S. Environmental Protection Agency

Allergan Receives 2017 ENERGY STAR® Partner Of The Year - Sustained Excellence Award From U.S. Environmental Protection Agency

-- Company Recognized with ENERGY STAR Award for Sixth Time --

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Doug Kass shares his thoughts on Tesla and the second quarter.

Weekly Roundup

Syria missile strike and U.S. jobs report cap a rugged week for markets. We make several portfolio moves, including a downgrade.

Allergan Teams Up With Media Mogul Wendy Williams To Debut The Patient Empowerment Campaign - Toilet Talk

Allergan Teams Up With Media Mogul Wendy Williams To Debut The Patient Empowerment Campaign - Toilet Talk

In Recognition of IBS Awareness Month, Allergan and the American Gastroenterological Association Work to Destigmatize the Bowel Health Conversation

Allergan Reports Topline Phase II Data Supporting Advancement Of BOTOX® (onabotulinumtoxinA) For The Treatment Of Major Depressive Disorder (MDD)

Allergan Reports Topline Phase II Data Supporting Advancement Of BOTOX® (onabotulinumtoxinA) For The Treatment Of Major Depressive Disorder (MDD)

BOTOX® is currently being studied as a potential treatment option for adult patients with moderate to severe Major Depressive Disorder (MDD)

Caterpillar, Allergan, Oclaro: Doug Kass' Views

Caterpillar, Allergan, Oclaro: Doug Kass' Views

Doug Kass shares his thoughts on Caterpillar, Allergan and Oclaro.

Weekly Roundup

That was quite a quarter, wasn't it? Portfolio moves include a downgrade of Apple.

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

This month's resilience in the market has a lot to do with short squeezes in big tech names.

Stocks Mixed as Wall Street Shakes Off Worries Over Trumpcare's Defeat

Stocks Mixed as Wall Street Shakes Off Worries Over Trumpcare's Defeat

Stocks are mixed on Monday as Wall Street shakes off worries over the way forward for the Trump White House.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.

Short Interest In Allergan Declines 39.3%

Short Interest In Allergan Declines 39.3%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 5,524,975 share decrease in total short interest for Allergan PLC , to 8,520,757, a decrease of 39.34% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Has Allergan's Pullback Ended?

Has Allergan's Pullback Ended?

Shares of Allergan are gaining for the third straight session and, at midday, are trading above last week's high.

Dow Drops Triple Digits as Trumpcare Fails, Worries Rise Over President's Agenda

Dow Drops Triple Digits as Trumpcare Fails, Worries Rise Over President's Agenda

Stocks fall on Monday morning as Donald Trump's failure to push through health care reform raises doubts over his ability to enact other promised changes.

Skincare Makers Lead Biotech Movers

Skincare Makers Lead Biotech Movers

Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.